PrimePro™/ PrimeMSK™

Phase 2Biologic

TThomas Advanced Medical LLC

PrimePro™/ PrimeMSK™ is one of 4 biologic programs targeting Mesenchymal Stem Cells. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Mesenchymal Stem CellsRecruiting

Mesenchymal Stem CellsPhase 2

Recruiting

Competition

Competitive Landscape

3 competitors in Mesenchymal Stem Cells

#DrugCompanyPhaseTrials

Allorx

TThe Foundation for Orthopaedics and Regenerative Medicine

Phase 1

6 2

PrimePro™/ PrimeMSK™

TThomas Advanced Medical LLC

Phase 2

1 3

Hmsc

SStemedica Cell Technologies, Inc.

Phase 2

1 4

Hexell-2020

HHexun Biosciences Co., LTD.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

Phase 1/2Recruiting

Mesenchymal Stem Cells

NCT04684602

Clinical

Trials by Indication[1]

Mesenchymal Stem Cells1 trial

Mesenchymal Stem Cells for the Treatment of Various Chronic and Acute Conditions

Recruiting·TThomas Advanced Medical LLC·Phase 1/2·NCT04684602·5,000 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for PrimePro™/ PrimeMSK™. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PrimePro™/ PrimeMSK™ compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PrimePro™/ PrimeMSK™. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Thomas Advanced Medical LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: TThomas Advanced Medical LLC

PrimePro™/ PrimeMSK™

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

Mesenchymal Stem Cells1 trial

References

Drug Info

Quick Facts

Related News